FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)

Background. FGFR1/2/3 fusions have been reported infrequently in aNSCLC, including as a rare, acquired resistance mechanism following treatment with EGFR TKIs. Data regarding their prevalence and therapeutic implications are limited. Methods. The Guardant Health (GH) electronic database (ED) was eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Raphael, Ari, Dudnik, Elizabeth, Hershkovitz, Dov, Jain, Suyog, Olsen, Steve, Soussan-Gutman, Lior, Ben-Shitrit, Taly, Dvir, Addie, Nechushtan, Hovav, Peled, Nir, Onn, Amir, Agbarya, Abed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102087/
https://www.ncbi.nlm.nih.gov/pubmed/35566609
http://dx.doi.org/10.3390/jcm11092475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102087/
https://www.ncbi.nlm.nih.gov/pubmed/35566609
http://dx.doi.org/10.3390/jcm11092475

Ejemplares similares